Primary Sclerosing Cholangitis

The Autoimmune Diseases, Fourth Edition

Volumn , Issue , 2006, Pages 767,XXVII-777,XXVII

  Vergani, Diego ^a   Mieli Vergani, Giorgina ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882859599     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012595961-2/50058-5     Document Type: Chapter

References (126)

1. K. Agarwal, M. Hudson and P. Harnson (2000) No association between primary sclerosing cholangitis (PSC) and CTLA-4 gene polymorphism: evidence against an autoimmune aetiology? J. Hepatol. 32 173A.
2. F. Alvarez, P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, E.L. Cancado, R.W. Chapman, W.G. Cooksley, A.J. Czaja, V.J. Desmet, P.T. Donaldson, A.L. Eddleston, L. Fainboim, J. Heathcote, J.C. Homberg, J.H. Hoofnagle, S. Kakumu, E.L. Krawitt, I.R. Mackay, R.N. MacSween, W.C. Maddrey, M.P. Manns, I.G. McFarlane, K.H. Meyer zum Buschenfelde and M. Zeniya (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31(5), 929-938.
3. P. Angulo and K.D. Lindor (1999) Primary sclerosing cholangitis. Hepatology 30(1), 325-332.
4. P. Angulo, J.B. Peter, M.E. Gershwin, C.K. DeSotel, Y. Shoenfeld, A.E. Ahmed and K.D. Lindor (2000) Serum autoantibodies in patients with primary sclerosing cholangitis. J. Hepatol. 32(2), 182-187.
5. K. Balasubramaniam, R.H. Wiesner and N.F. LaRusso (1988) Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 95(5), 1395.
6. K. Bambha, W.R. Kim, J. Talwalkar, H. Torgerson, J.T. Benson, T.M. Therneau, E.V. Loftus Jr., B.P. Yawn, E.R. Dickson and L.J. Melton 3rd. (2003) Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125(5), 1364-1369.
7. W. Bernal, M. Moloney, J. Underhill and P.T. Donaldson (1999) Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J. Hepatol. 30(2), 237-241.
8. K.M. Boberg, O. Fausa, T. Haaland, E. Holter, O.J. Mellbye, A. Spurkland and E. Schrumpf (1996) Features of autoimmune hepatitis in primary scleorising cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 23(6), 1369-1376.
9. K.M. Boberg, E. Aadland, J. Jahnsen, N. Raknerud, M. Stiris and H. Bell (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33(1), 99-103.
10. R.W. Boden, J.G. Rankin, S.J. Goulston and W. Morrow (1959) The liver in ulcerative colitis: the significance of raised serum-alkalinephosphatase levels. Lancet 2 245-248.
11. H.C. Bodenheimer Jr., N.F. LaRusso, W.R. Thayer Jr., C. Charland, P.J. Staples and J. Ludwig (1983) Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 3(2), 150-154.
12. G. Bouma and W. Strober (2003) The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3(7), 521-533.
13. B.N. Brooke, P.W. Dykes and F.C. Walker (1961) A study of liver disorder in ulcerative colitis. Postgrad. Med. J. 37 245-251.
14. U. Broome, H. Glaumann, R. Hultcrantz and U. Forsum (1990) Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 25(1), 54-58.
15. J.R. Cangemi, R.H. Wiesner, S.J. Beaver, J. Ludwig, R.L. MacCarty, R.R. Dozois, A.R. Zinsmeister and N.F. LaRusso (1989) Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96(3), 790-794.
16. J.B. Carey (1964) Bile acids, cirrhosis, and human evolution. Gastroenterology 46 490-493.
17. R. Chapman (1995) Does HLA status influence prognosis in primary sclerosing cholangitis? Gastroenterology 108(3), 937-940.
18. R.W. Chapman, Z. Varghese, R. Gaul, G. Patel, N. Kokinon and S. Sherlock (1983) Association of primary sclerosing cholangitis with HLA-B8. Gut 24(1), 38-41.
19. R.W. Chapman, M. Cottone, W.S. Selby, H.A. Shepherd, S. Sherlock and D.P. Jewell (1986) Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 27(1), 86-91.
20. R.W. Chapman, P.M. Kelly, A. Heryet, D.P. Jewell and K.A. Fleming (1988) Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 29(4), 422-427.
21. W.J. Cromartie, J.G. Craddock, J.H. Schwab, S.K. Anderle and C.H. Yang (1977) Arthritis in rats after systemic injection of streptococcal cells or cell walls. J. Exp. Med. 146(6), 1585-1602.
22. S. Cullen and R. Chapman (2003) Primary sclerosing cholangitis. Autoimmun. Rev. 2(6), 305-312.
23. P. Delbet (1924) Retrecissement du choledoque: cholecystoduodenostomie. Bull. Mem. Soc. Nat. Chir. 50 1144-1146.
24. A. Dikengil, B.N. Siskind, S.S. Morse, A. Swedlund, K.E. Bober-Sorcinelli and M.I. Burrell (1986) Sclerosing cholangitis from intraarterial floxuridine. J. Clin. Gastroenterol. 8(6), 690-693.
25. P.T. Donaldson and S. Norris (2002) Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 35(8), 555-564.
26. P.T. Donaldson, J.M. Farrant, M.L. Wilkinson, K. Hayllar, B.C. Portmann and R. Williams (1991) Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 13(1), 129-133.
27. P.T. Donaldson, S. Norris, P.K. Constantini, W. Bernal, P. Harrison and R. Williams (2000) The interleukin-1 and interleukin-10 gene polymorphosms in primary sclerosing cholangitis: no associations with disease susceptibility/resistance. J. Hepatol. 32(6), 882-886.
28. J.L. Doppman and M.E. Girton (1984) Bile duct scarring following ethanol embolization of the hepatic artery: an experimental study in monkeys. Radiology 152(3), 621-626.
29. J.M. Farrant, K.M. Hayllar, M.L. Wilkinson, J. Karani, B.C. Portmann, D. Westaby and R. Williams (1991) Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100(6), 1710-1717.
30. J.M. Farrant, D.G. Doherty, P.T. Donaldson, R.W. Vaughan, K.M. Hayllar, K.I. Welsh, A.L. Eddleston and R. Williams (1992) Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 16(2), 390-395.
31. O. Fausa, E. Schrumpf and K. Elgjo (1991) Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin. Liver Dis. 11(1), 31-39.
32. R.B. Feller, R.C. Waugh, W.S. Selby, P.M. Dolan, A.G. Sheil and G.W. McCaughan (1996) Biliary strictures after liver transplantation: clinical picture, correlates and outcomes. J. Gastroenterol. Hepatol. 11(1), 21-25.
33. M.J. Finegold and R.J. Carpenter (1982) Obliterative cholangitis due to cytomegalovirus: a possible precursor of paucity of intrahepatic bile ducts. Hum. Pathol. 13(7), 662-665.
34. J.G. Fox, F.E. Dewhirst, Z. Shen, Y. Feng, N.S. Taylor, B.J. Paster, R.L. Ericson, C.N. Lau, P. Correa, J.C. Araya and I. Roa (1998) Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 114(4), 755-763.
35. A. Frenzer, W. Fierz, E. Rundler, B. Hammer and J. Binek (1998) Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 13(9), 950-954.
36. P.J. Gow and R.W. Chapman (2000) Liver transplantation for primary sclerosing cholangitis. Liver 20(2), 97-103.
37. A.J. Grant, P.F. Lalor, M. Salmi, S. Jalkanen and D.H. Adams (2002) Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359(9301), 150-157.
38. I.W. Graziadei, R.H. Wiesner, P.J. Marotta, M.K. Porayko, J.E. Hay, M.R. Charlton, J.J. Poterucha, C.B. Rosen, G.J. Gores, N.F. LaRusso and R.A. Krom (1999) Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30(5), 1121-1127.
39. G.V. Gregorio, B. Portmann, J. Karani, P. Harrison, P.T. Donaldson, D. Vergani, et al. (2001) Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33(3), 544-553.
40. H. Gur, G. Shen, M. Sutjita, J. Terrberry, I. Alosachie, N. Barka, H.C. Lin, J.B. Peter, P.L. Meroni and M. Kaplan (1995) Autoantibody profile of primary sclerosing cholangitis. Pathobiology 63(2), 76-82.
41. D.M. Harnois, P. Angulo, R.A. Jorgensen, N.F. Larusso and K.D. Lindor (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 96(5), 1558-1562.
42. R.F. Harrison, M.H. Davies, J.M. Neuberger and S.G. Hubscher (1994) Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 20(2), 356-361.
43. I.B. Holubitsky and A.D. McKenzie (1964) Primary sclerosing cholangitis of the extrahepatic bile ducts. Can. J. Surg. 115 277-283.
44. W. Hu, B.R. Blazar, J.C. Manivel, K. Paradis and H.L. Sharp (1996) Phenotypical and functional characterization of intrahepatic bile duct cells from common duct ligated mice. J. Lab. Clin. Med. 128(6), 536-544.
45. S.L. Javett (1971) Azathioprine in primary sclerosing cholangitis. Lancet 1(7703), 810.
46. P.J. Johnson and I.G. McFarlane (1993) Meeting report: International Autoimmune Hepatitis Group Hepatology 18 998-1005. 4
47. E. Judd (1926) Stricture of the common bile duct. Ann. Surg. 84 404.
48. M.M. Kaplan (1991) Medical approaches to primary sclerosing cholangitis. Semin. Liver Dis. 11(1), 56-63.
49. R. Klein, J. Eisenburg, P. Weber, F. Seibold and P.A. Berg (1991) Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 14(6), 1147-1152.
50. K. Kuroe, Y. Haga, O. Funakoshi, I. Mizuki, K. Kanazawa and Y. Yoshida (1996) Extraintestinal manifestations of granulomatous enterocolitis induced in rabbits by long-term submucosal administration of muramyl dipeptide emulsified with Freund's incomplete adjuvant. J. Gastroenterol. 31(2), 199-206.
51. K. Kuroe, Y. Haga, O. Funakoshi, K. Kanazawa, I. Mizuki and Y. Yoshida (1996) Pericholangitis in a rabbit colitis model induced by injection of muramyl dipeptide emulsified with a long-chain fatty acid. J. Gastroenterol. 31(3), 347-352.
52. R. Lafourcade (1925) Deux observations d'obliteration cicatricielle du choledoque. Anastomose laterale entre le choledoque et le duodenum dans le premier cas. Recontruction par prothese avec tube de caoutchouc dans le second. Bull. Mem. Soc. Nat. Chir. 51 828-831.
53. S.P. Lawrence, K.E. Sherman, J.M. Lawson and Z.D. Goodman (1994) A 39 year old man with chronic hepatitis. Semin. Liver Dis. 14(1), 97-105.
54. D. Le Thi Huong, C. de Gennes, L. Guillevin, B. Wechsler, S.D. Etienne, O. Bletry and P. Godeau (1989) The liver and periarteritis nodosa. Gastroenterol. Clin. Biol. 13(2), 141-148.
55. Y.M. Lee and M.M. Kaplan (1995) Primary sclerosing cholangitis. N. Engl. J. Med. 332(14), 924-933.
56. S.N. Lichtman and R.B. Sartor (1991) Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats. Immunol. Res. 10(3–4), 528-531.
57. S.N. Lichtman, R.B. Sartor, J. Keku and J.H. Schwab (1990) Hepatic inflammation in rats with experimental small intestinal bacterial over-growth. Gastroenterology 98(2), 414-423.
58. S.N. Lichtman, J. Keku, R.L. Clark, J.H. Schwab and R.B. Sartor (1991) Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 13(4), 766-772.
59. S.N. Lichtman, J. Keku, J.H. Schwab and R.B. Sartor (1991) Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect. Immun. 59(2), 555-562.
60. S.N. Lichtman, J. Keku, J.H. Schwab and R.B. Sartor (1991) Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 100(2), 513-519.
61. S.N. Lichtman, E.E. Okoruwa, J. Keku, J.H. Schwab and R.B. Sartor (1992) Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J. Clin. Invest. 90(4), 1313-1322.
62. S.N. Lichtman, J. Wang and R.L. Clark (1995) A microcholangiographic study of liver disease models in rats. Acad. Radiol. 2(6), 515-521.
63. K.D. Lindor (1997) Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group N. Engl. J. Med. 336(10), 691-695.
64. K.D. Lindor, R.H. Wiesner, J.A. Katzmann, N.F. LaRusso and S.J. Beaver (1987) Lymphocyte subsets in primary sclerosing cholangitis. Dig. Dis. Sci. 32(7), 720-725.
65. T. Lister (1899) A specimen of diffuse ulcerative colitis with secondary diffuse hepatitis. Trans. Pathol. Soc. Lon. 50 130-134.
66. E.V. Loftus Jr., H.I. Aguilar, W.J. Sandborn, W.J. Tremaine, R.A. Krom, A.R. Zinsmeister, I.W. Graziadei and R.H. Wiesner (1998) Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 27(3), 685-690.
67. M.S. Longhi, Y. Ma, D.P. Bogdanos, P. Cheeseman, G. Mieli-Vergani and D. Vergani (2004) Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J. Hepatol. 41(1), 31-37.
68. J. Ludwig, N. La Russo and R.H. Wiesner (1986) Primary sclerosing cholangitis. R.L. Peters, J.R. Craig (Eds) Contemporary views in surgical pathology New York: Churchill Livingstone
69. J. Ludwig, C.H. Kim, R.H. Wiesner and R.A. Krom (1989) Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 9(2), 215-218.
70. A.R. MacLean, L. Lilly, Z. Cohen, B. O'Connor and R.S. McLeod (2003) Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis. Dis. Colon Rectum 46(8), 1124-1128.
71. A. Mandal, A. Dasgupta, L. Jeffers, L. Squillante, S. Hyder, R. Reddy, et al. (1994) Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 106(1), 185-192.
72. I.G. McFarlane, B.M. Wojcicka, D.C. Tsantoulas, B.C. Portmann, A.L. Eddleston and R. Williams (1979) Leukocyte migration inhibition in response to biliary antigens in primary biliary cirrhosis, sclerosing cholangitis, and other chronic liver diseases. Gastroenterology 76(6), 1333-1340.
73. W.Z. Mehal, Y.M. Lo, B.P. Wordsworth, J.M. Neuberger, S.C. Hubscher, K.A. Fleming and R.W. Chapman (1994) HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 106(1), 160-167.
74. R. Miller (1927) Benign stricture of common bile duct. Ann. Surg. 86 296-303.
75. G.Y. Minuk, M. Angus, C.M. Brickman, T.J. Lawley, M.M. Frank, J.H. Hoofnagle and E.A. Jones (1985) Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 88(1), 166-170. Pt 1
76. S.A. Mitchell, D.S. Bansi, N. Hunt, K. Von Bergmann, K.A. Fleming and R.W. Chapman (2001) A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121(4), 900-907.
77. S.A. Mitchell, J. Grove, A. Spurkland, K.M. Boberg, K.A. Fleming, C.P. Day, E. Schrumpf and R.W. Chapman (2001) Association of the tumour necrosis factor alpha-308 but not the interleukin 10–627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 49(2), 288-294.
78. M.M. Moloney, L.J. Thomson, M.J. Strettell, R. Williams and P.T. Donaldson (1998) Human leukocyte antigen-C genes and susceptibility to primary sclerosing cholangitis. Hepatology 28(3), 660-662.
79. M. Mourelle, A. Salas, J. Vilaseca, F. Guarner and J.R. Malagelada (1995) Induction of chronic cholangitis in the rat by trinitrobenzenesulfonic acid. J. Hepatol. 22(2), 219-225.
80. R.N. Myers, J.H. Cooper and N. Padis (1970) Primary sclerosing cholangitis. Complete gross and histologic reversal after long-term steroid therapy. Am. J. Gastroenterol. 53(6), 527-538.
81. S. Narumi, J.P. Roberts, J.C. Emond, J. Lake and N.L. Ascher (1995) Liver transplantation for sclerosing cholangitis. Hepatology 22(2), 451-457.
82. G.T. Nepom (1990) A unified hypothesis for the complex genetics of HLA associations with IDDM. Diabetes 39(10), 1153-1157.
83. S. Norris, E. Kondeatis, R. Collins, J. Satsangi, M. Clare, R. Chapman, H. Stephens, P. Harrison, R. Vaughan and P. Donaldson (2001) Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 120(6), 1475-1482.
84. O. Olerup, R. Olsson, R. Hultcrantz and U. Broome (1995) HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 108(3), 870-878.
85. R. Olsson, A. Danielsson, G. Jarnerot, E. Lindstrom, L. Loof, P. Rolny, B.O. Ryden, C. Tysk and S. Wallerstedt (1991) Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100(5), 1319-1323. Pt 1
86. T. Orth, M. Neurath, P. Schirmacher, U. Treichel, K.H. Meyer zum Buschenfelde and W. Mayet (1999) Anti-neutrophil cytoplasmic antibodies in a rat model of trinitrobenzenesulphonic acid-induced liver injury. Eur. J. Clin. Invest. 29(11), 929-939.
87. T. Orth, M. Neurath, P. Schirmacher, P.R. Galle and W.J. Mayet (2000) A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF-alpha production and autoantibodies. J. Hepatol. 33(6), 862-872.
88. R.H. Palmer (1972) Bile acids, liver injury, and liver disease. Arch. Intern. Med. 130(4), 606-617.
89. G.V. Papatheodoridis, M. Hamilton, P.K. Mistry, B. Davidson, K. Rolles and A.K. Burroughs (1998) Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 43(5), 639-644.
90. C.Y. Ponsioen, J. Defoer, F.J. Ten Kate, G.J. Weverling, G.N. Tytgat, Y. Pannekoek and P.M. Wertheim-Dillen (2002) A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? Eur. J. Gastroenterol. Hepatol. 14(6), 641-648.
91. M.K. Porayko, R.H. Wiesner, N.F. LaRusso, J. Ludwig, R.L. MacCarty, B.L. Steiner, C.K. Twomey and A.R. Zinsmeister (1990) Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 98(6), 1594-1602.
92. E.M. Quigley, N.F. LaRusso, J. Ludwig, R.N. MacSween, G.G. Birnie and G. Watkinson (1983) Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 85(5), 1160-1165.
93. M. Rabinovitz, J.S. Gavaler, R.R. Schade, V.J. Dindzans, M.C. Chien and D.H. Van Thiel (1990) Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 11(1), 7-11.
94. M. Rabinovitz, A.J. Demetris, C.F. Bou-Abboud and D.H. Van Thiel (1992) Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig. Dis. Sci. 37(10), 1606-1611.
95. S. Saarinen, U. Broome and A. Ligers (1998) CTLA-4 gene polymorphism associated with primary sclerosing cholangitis (PSC). J. Hepatol. 28 125A.
96. R.B. Sartor, H.C. Rath, S.N. Lichtman and E.A. van Tol (1996) Animal models of intestinal and joint inflammation. Baillières Clin. Rheumatol. 10(1), 55-76.
97. J. Satsangi, R.W. Chapman, N. Haldar, P. Donaldson, S. Mitchell, J. Simmons, S. Norris, S.E. Marshall, J.I. Bell, D.P. Jewell and K.I. Welsh (2001) A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 121(1), 124-130.
98. E. Schrumpf, O. Fausa, O. Forre, J.H. Dobloug, S. Ritland and E. Thorsby (1982) HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand. J. Gastroenterol. 17(2), 187-191.
99. E. Schrumpf and K.M. Boberg (2001) Epidemiology of primary sclerosing cholangitis. Best Pract. Res. Clin. Gastroenterol. 15(4), 553-562.
100. G. Senaldi, P.T. Donaldson, S. Magrin, J.M. Farrant, G.J. Alexander, D. Vergani and R. Williams (1989) Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 97(6), 1430-1434.
101. H.A. Shepherd, W.S. Selby, R.W. Chapman, D. Nolan, C. Barbatis, J.O. McGee and D.P. Jewell (1983) Ulcerative colitis and persistent liver dysfunction. Quart. J. Med. 52(208), 503-513.
102. R. Sheng, A.B. Zajko, W.L. Campbell and K. Abu-Elmagd (1993) Biliary strictures in hepatic transplants: prevalence and types in patients with primary sclerosing cholangitis vs those with other liver diseases. AJR Am. J. Roentgenol. 161(2), 297-300.
103. J.H. Siegel, S. Barnes and J.S. Morris (1977) Bile acids in liver disease associated with inflammatory bowel disease. Digestion 15(6), 469-481.
104. J.A. Snook, R.W. Chapman, G.K. Sachdev, A. Heryet, P.M. Kelly, K.A. Fleming and D.P. Jewell (1989) Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J. Hepatol. 9(1), 36-41.
105. A. Spurkland, S. Saarinen, K.M. Boberg, S. Mitchell, U. Broome, L. Caballeria, E. Ciusani, R. Chapman, G. Ercilla, O. Fausa, I. Knutsen, A. Pares, F. Rosina, O. Olerup, E. Thorsby and E. Schrumpf (1999) HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 53(5), 459-469.
106. S.R. Targan, C. Landers, A. Vidrich and A.J. Czaja (1995) High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108(4), 1159-1166.
107. B. Terjung and H.J. Worman (2000) “ANCA” in liver diseases. M.P. Manns, P.G. Manns, U. Leuschner,(Eds) Immunology and Liver London: Kluwer 137-151.
108. B. Terjung, U. Spengler, T. Sauerbruch and H.J. Worman (2000) “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119(2), 310-322.
109. B. Terjung, H.J. Worman, V. Herzog, T. Sauerbruch and U. Spengler (2001) Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin. Exp. Immunol. 126(1), 37-46.
110. K. Tjandra, K.A. Sharkey and M.G. Swain (2000) Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 31(2), 280-290.
111. Y. Ueno, J.O. Phillips, J. Ludwig, S.N. Lichtman and N.F. LaRusso (1996) Development and characterization of a rodent model of immune-mediated cholangitis. Proc. Natl. Acad. Sci. U.S.A. 93(1), 216-220.
112. A. Ueno, N. Kono, H. Minato and Y. Nakanuma (1998) Diffuse biliary tract involvement mimicking primary sclerosing cholangitis in an experimental model of chronic graft-versus-host disease in mice. Pathol. Int. 48(6), 421-427.
113. D.H. Van Thiel, P. Carroll, K. Abu-Elmagd, H. Rodriguez-Rilo, W. Irish, J. McMichael and T.E. Starzl (1995) Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. 90(3), 455-459.
114. A. Vera, B.K. Gunson, V. Ussatoff, P. Nightingale, D. Candinas, S. Radley, A.D. Mayer, J.A. Buckels, P. McMaster, J. Neuberger and D.F. Mirza (2003) Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75(12), 1983-1988.
115. J.M. Vierling (1998) Aetiopathogenesis of primary sclerosing cholangitis. M.P. Manns, A. Stieihl, R.H. Wiesner (Eds) Primary sclerosis cholangitis London: Kluwer Academic Publishers 9.
116. J.M. Vierling, W.B. Ruderman, B.D. Jaffee, R.H. Fennell Jr. and H.N. Claman (1989) Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens. A reproducible model of nonsuppurative destructive cholangitis. Transplantation 48(4), 717-718.
117. K.W. Warren, S. Athanassiades and J.I. Monge (1966) Primary sclerosing cholangitis. A study of forty-two cases. Am. J. Surg. 111(1), 23-38.
118. A. Wee and J. Ludwig (1985) Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann. Intern. Med. 102(5), 581-587.
119. T.L. Whiteside, S. Lasky, L. Si and D.H. Van Thiel (1985) Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 5(3), 468-474.
120. K. Wiencke, A. Spurkland, E. Schrumpf and K.M. Boberg (2001) Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 34(4), 625-630. Pt 1
121. R.H. Wiesner and N.F. LaRusso (1980) Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 79(2), 200-206.
122. R.H. Wiesner, P.M. Grambsch, E.R. Dickson, J. Ludwig, R.L. MacCarty, E.B. Hunter, T.R. Fleming, L.D. Fisher, S.J. Beaver and N.F. LaRusso (1989) Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10(4), 430-436.
123. S. Yamada, M. Ishii, L.S. Liang, T. Yamamoto and T. Toyota (1994) Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. J. Gastroenterol. 29(5), 631-636.
124. S. Yamada, M. Ishii, N. Kisara, R. Nagatomi and T. Toyota (1999) Macrophages are essential for lymphocyte infiltration in formyl peptide-induced cholangitis in rat liver. Liver 19(3), 253-258.
125. D. Zauli, E. Schrumpf, C. Crespi, F. Cassani, O. Fausa and E. Aadland (1987) An autoantibody profile in primary sclerosing cholangitis. J. Hepatol. 5(1), 14-18.
126. D. Zauli, S. Ghetti, A. Grassi, C. Descovich, F. Cassani, G. Ballardini, L. Muratori and F.B. Bianchi (1997) Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25(5), 1105-1107.